Evidence map›Paper›PMID 37953874›Full record

ReviewAsian journal of pharmaceutical sciences2023

Nanotechnologies meeting natural sources: Engineered lipoproteins for precise brain disease theranostics.

Ruoning Wang, Xinru Zhang, Kuanhan Feng, Wei Zeng, Jie Wu, Danni Sun, Ziyi Lu, Hao Feng, Liuqing Di

Open access · diamondAbstract readReview
In one paragraph

Review in Asian journal of pharmaceutical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ruoning WangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Xinru ZhangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Kuanhan FengSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Wei ZengSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jie WuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Danni SunSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Ziyi LuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Hao FengSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Liuqing DiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological nanotechnologies have provided considerable opportunities in the management of malignancies with delicate design and negligible toxicity, from preventive and diagnostic to therapeutic fields. Lipoproteins, because of their inherent blood-brain barrier permeability and lesion-homing capability, have been identified as promising strategies for high-performance theranostics of brain diseases. However, the application of natural lipoproteins remains limited owing to insufficient accumulation and complex purification processes, which can be critical for individual therapeutics and clinical translation. To address these issues, lipoprotein-inspired nano drug-delivery systems (nano-DDSs), which have been learned from nature, have been fabricated to achieve synergistic drug delivery involving site-specific accumulation and tractable preparation with versatile physicochemical functions. In this review, the barriers in brain disease treatment, advantages of state-of-the-art lipoprotein-inspired nano-DDSs, and bio-interactions of such nano-DDSs are highlighted. Furthermore, the characteristics and advanced applications of natural lipoproteins and tailor-made lipoprotein-inspired nano-DDSs are summarized. Specifically, the key designs and current applications of lipoprotein-inspired nano-DDSs in the field of brain disease therapy are intensively discussed. Finally, the current challenges and future perspectives in the field of lipoprotein-inspired nano-DDSs combined with other vehicles, such as exosomes, cell membranes, and bacteria, are discussed.

Indexed as

Biological modulationBlood-brain barrierBrain diseasesLipoproteinsTheranostics

Identifiers

PMID37953874
PMCPMC10637878
OpenAlexW4387783630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.